Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

@article{Rssner2000WeightLW,
  title={Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.},
  author={Stephan R{\"o}ssner and Lars V Sj{\"o}str{\"o}m and Rudolf Noack and Arend Edo Meinders and Giorgio Noseda},
  journal={Obesity research},
  year={2000},
  volume={8 1},
  pages={
          49-61
        }
}
OBJECTIVE To determine the effect of orlistat, a new lipase inhibitor, on long-term weight loss, to determine the extent to which orlistat treatment minimizes weight regain in a second year of treatment, and to assess the effects of orlistat on obesity-related risk factors. RESEARCH METHODS AND PROCEDURES This was a 2-year, multicenter, randomized, double-blind, placebo-controlled study. Obese patients (body mass index 28 to 43 kg/m2) were randomized to placebo or orlistat (60 or 120 mg… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 130 CITATIONS

Results of obesity treatment.

  • Annales d'endocrinologie
  • 2002
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Pragmatic study of orlistat 60 mg on abdominal obesity

  • European Journal of Clinical Nutrition
  • 2011
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Pharmacological treatment of the overweight patient.

  • Pharmacological reviews
  • 2007
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2000
2019

CITATION STATISTICS

  • 9 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.

  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1995
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Treatment for 21⁄2 years with sibutramine

DH Ryan, GA Bray, DA Williamson, CM. Champagne
  • Obes Res.1996; 4(Suppl. 1):AO73
  • 2000
VIEW 2 EXCERPTS

Efficacy and tolerability of orlistat in the treatment of obesity : a 6 month dose ranging study

LF VanGaal, JI Broom, G Enzi, H Toplak
  • Eur J Clin Pharmacol
  • 1998

Mode of action of orlistat.

  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1997
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…